Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies

Cancer Immunology, Immunotherapy(2025)10.1007/s00262-025-04247-1Source: DataRank Database

Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies is a research paper published in Cancer Immunology, Immunotherapy (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time.

N/A

0.104DataRank · unranked

Scored on demand from live citation data

1 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.46)OA: goldTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.104

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (9)

Yan Yu ORCID,Linzhi Xie,Liwen Wang ORCID,Yuhan Yan,Qian Cheng

Live enrichment

PubMed:41410870 PMC:PMC12715080 OpenAlex:https://openalex.org/W4417459029

Fundamental Research Funds for Central Universities of the Central South University

Grant: 2025ZZTS0194

National Natural Science Foundation of China

Grant: 82170204

Beijing Medical and Health Foundation

Grant: JSZ021

FWCI

0.46

Citation Percentile

0.7%

Citation Trend

2026

goldLicense: cc-by-nc-nd

journalhttps://link.springer.com/content/pdf/10.1007/s00262-025-04247-1.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-025-04247-1.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-025-04247-1

journalhttps://doi.org/10.1007/s00262-025-04247-1

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41410870

Fields of Study

CAR-T cell therapy researchT-cell and B-cell ImmunologyProtein Degradation and InhibitorsThalidomideHumansAnimalsTumor MicroenvironmentMiceImmunotherapy, AdoptiveXenograft Model Antitumor AssaysReceptors, Chimeric AntigenMultiple MyelomaCell Line, TumorLymphoma

MeSH Terms

Receptors, Chimeric AntigenAnimalsHumansLymphomaMultiple MyelomaThalidomideImmunotherapy, AdoptiveXenograft Model Antitumor AssaysCell Line, TumorMiceTumor Microenvironment

Keywords

PomalidomideTumor microenvironmentImmune systemImmunotherapyCytotoxic T cellFunction (biology)Refractory (planetary science)T cellMemory T CellImmune MicroenvironmentLymphoid MalignanciesCar-t Therapy

Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies

FAIR Checklist

DataRank Breakdown

Authors (9)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)